Emmanuel Mas, Osvaldo Borrelli, Ilse Broekaert, J. Martin de-Carpi, Jernej Dolinsek, Erasmo Miele, Corina Pienar, C. Ribes Koninckx, Ruth-Anne Thomassen, Mike Thomson, Christo Tzivinikos, Marc A. Benninga
Hôpital des Enfants and Université de Toulouse. Great Ormond Street Hospital. University Hospital Cologne and University of Cologne. Hospital Sant Joan de Déu. University Medical Centre Maribor. University of Naples “Federico II”. “Victor Babes” University of Medicine and Pharmacy. La Fe University Hospital. Oslo University Hospital. Sheffield Children’s Hospital NHS Foundation Trust. Al Jalila Children’s Specialty Hospital. Emma Children’s Hospital and University of Amsterdam.
France, United Kingdom, Germany, Spain, Slovenia, Italy, Romania, Norway, United Arab Emirates, Netherlands
Pediatric Gastroenterology and Nutrition
Pediatr Gastroenterol Nutr 2022; 74: 1-6
DOI: 10.1097/MPG.0000000000003294
Abstract
Octreotide, a somatostatin analogue, has been used for more than 20 years in children with gastrointestinal bleeding, chylothorax or chylous ascites, intestinal lymphangiectasia, pancreatitis, intestinal dysmotility, and severe diarrhoea; however, until now, there is a lack of randomised clinical trials evaluating the efficacy of this compound in childhood. Hence, we aimed to review the literature in order to determine the evidence of its use and safety in children, using PubMed from 2000 to 2021 with the search terms “octreotide” and “children” and “bleeding or chylous ascites or chylothorax or acute pancreatitis or lymphangiectasia or diarrhoea or intestinal dysmotility”.
Category
Pulmonary Lymphatic Disease
Medical Therapy. Efficacy or Lack of Efficacy
Review Articles Concerning Pulmonary Vascular Disease
Age Focus: Pediatric Pulmonary Vascular Disease
Fresh or Filed Publication: Filed (PHiled). Greater than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: Yes